Rosuvastatin – A Highly Effective New 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase Inhibitor: Review of Clinical Trial Data at 10–40 mg Doses in Dyslipidemic Patients

By  

Cardiology, Vol. 99, Iss. 3, 2003-06 ,pp. : 126-139

Karger

Access to resources Recommend Favorite

Clinical evaluation of rosuvastatin in heart transplant patients with hypercholesterolemia and therapeutic failure of other statin regimens: short‐term and long‐term efficacy and safety results

By  

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 28, Iss. 9, 2015-09 ,pp. : 1034-1041

John Wiley & Sons Inc

Access to resources Recommend Favorite

Telomere length and outcomes in ischaemic heart failure: data from the COntrolled ROsuvastatin multiNAtional Trial in Heart Failure (CORONA)

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 3, 2015-03 ,pp. : 313-319

John Wiley & Sons Inc

Access to resources Recommend Favorite

A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study)

By Zhu Jun-ren   Tomlinson Brian   Ro Young Moo   Sim Kui-Hian   Lee Yuan-Teh   Sriratanasathavorn Charn  

Current Medical Research and Opinion, Vol. 23, Iss. 12, 2007-12 ,pp. : 3055-3068

Informa Healthcare

Access to resources Recommend Favorite

Rosuvastatin: the most efficient treatment option for patients with dyslipidemia

By Tuomilehto Jaakko  

Future Lipidology, Vol. 2, Iss. 2, 2007-04 ,pp. : 127-141

Future Medicine

Access to resources Recommend Favorite